All Stories

  1. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy

    Article • International Journal of Chronic Obstructive Pulmonary Disease, June 2017, Dove Medical Press

    Dr Douglas Mapel, Dominic PIlon

  2. Application of the new GOLD COPD staging system to a US primary care cohort, with comparison to physician and patient impressions of severity

    Article • International Journal of Chronic Obstructive Pulmonary Disease, July 2015, Dove Medical Press

    Dr Douglas Mapel, Alyssa Goolsby Hunter

  3. A Clinical Study of COPD Severity Assessment by Primary Care Physicians and Their Patients Compared with Spirometry

    Article • The American Journal of Medicine, June 2015, Elsevier

    Dr Douglas Mapel

  4. The impact of chronic pain on direct medical utilization and costs in chronic obstructive pulmonary disease

    Article • ClinicoEconomics and Outcomes Research, March 2015, Taylor & Francis

    Dr Douglas Mapel

  5. The epidemiology and treatment of anal fissures in a population-based cohort

    Article • BMC Gastroenterology, July 2014, Springer Science + Business Media

    Dr Douglas Mapel

  6. Management of Asthma and Chronic Obstructive Pulmonary Disease with Combination Inhaled Corticosteroids and Long-Acting β-Agonists: A Review of Comparative Effectiveness Research

    Article • Drugs, May 2014, Springer Science + Business Media

    Dr Douglas Mapel

  7. Renal and hepatobiliary dysfunction in chronic obstructive pulmonary disease

    Article • Current Opinion in Pulmonary Medicine, March 2014, Wolters Kluwer Health

    Dr Douglas Mapel

  8. Functional disorders of the gastrointestinal tract: Cost effectiveness review

    Article • Best Practice & Research Clinical Gastroenterology, December 2013, Elsevier

    Dr Douglas Mapel

  9. Cardiovascular Comorbidity in COPD

    Article • CHEST Journal, October 2013, Elsevier

    Dr Douglas Mapel

  10. Chronic Pain and Pain Medication Use in Chronic Obstructive Pulmonary Disease. A Cross-Sectional Study

    Article • Annals of the American Thoracic Society, August 2013, American Thoracic Society

    Dr Douglas Mapel

  11. Prevalence of renal and hepatobiliary disease, laboratory abnormalities, and potentially toxic medication exposures among persons with COPD

    Article • International Journal of Chronic Obstructive Pulmonary Disease, March 2013, Taylor & Francis

    Dr Douglas Mapel

  12. New Clinical Insights into Chronic Obstructive Pulmonary Disease and Their Implications for Pharmacoeconomic Analyses

    Article • PharmacoEconomics, October 2012, Springer Science + Business Media

    Dr Douglas Mapel

  13. The Epidemiology, Diagnosis, and Cost of Dyspepsia and H elicobater pylori Gastritis: A Case–Control Analysis in the S outhwestern U nited...

    Article • Helicobacter, September 2012, Wiley

    Dr Douglas Mapel

  14. Changes in COPD demographics and costs over 20 years

    Article • Journal of Medical Economics, August 2012, Informa Healthcare

    Dr Douglas Mapel

  15. Smoking Cessation Histories: Internet Questionnaire Versus Telephone Interview

    Article • May 2012, American Thoracic Society

    Dr Douglas Mapel

  16. Limited Lung Function: Impact Of Reduced Peak Expiratory Flow On Health Status, Health Care Utilization, And Expected Survival In Older Adults

    Article • May 2012, American Thoracic Society

    Dr Douglas Mapel

  17. Undertreatment of COPD: a retrospective analysis of US managed care and Medicare patients

    Article • International Journal of Chronic Obstructive Pulmonary Disease, January 2012, Taylor & Francis

    Dr Douglas Mapel

  18. Insights into COPD Comorbidities from the OLIN Study and Other Large Databases

    Article • COPD Journal of Chronic Obstructive Pulmonary Disease, December 2011, Taylor & Francis

    Dr Douglas Mapel

  19. Prevalence of Airway Obstruction Assessed by Lung Function Questionnaire

    Article • Mayo Clinic Proceedings, May 2011, Elsevier

    Dr Douglas Mapel

  20. Effectiveness Of Inhaled Corticosteroid/Long-Acting ß2-Agonist (ICS/LABA) Combination Therapies Among Chronic Obstructive Pulmonary Disease (COPD) Patients Stratified By Pre-Therapy Short-Acting ?2-Agonist (SABA) Use

    Article • May 2011, American Thoracic Society

    Dr Douglas Mapel

  21. Comparative Effectiveness Of Fluticasone Propionate/salmeterol (250/50mcg) Combination And Anticholinergics As Initial Maintenance Therapy For Chronic Obstructive Pulmonary Disease: A Retrospective Observational Cohort Study

    Article • May 2011, American Thoracic Society

    Dr Douglas Mapel

  22. Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data

    Article • BMC Health Services Research, February 2011, Springer Science + Business Media

    Dr Douglas Mapel

  23. Economic burden of chronic bronchitis in the United States: a retrospective case-control study

    Article • International Journal of Chronic Obstructive Pulmonary Disease, January 2011, Taylor & Francis

    Dr Douglas Mapel

  24. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management

    Article • Journal of Medical Economics, January 2011, Informa Healthcare

    Dr Douglas Mapel

  25. Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease

    Article • International Journal of Chronic Obstructive Pulmonary Disease, December 2010, Taylor & Francis

    Dr Douglas Mapel

  26. Impact of maintenance therapy on hospitalization and expenditures for medicare beneficiaries with chronic obstructive pulmonary disease

    Article • The American Journal of Geriatric Pharmacotherapy, October 2010, Elsevier

    Dr Douglas Mapel

  27. Adherence to controller therapy for chronic obstructive pulmonary disease: a review

    Article • Current Medical Research and Opinion, September 2010, Informa Healthcare

    Dr Douglas Mapel

  28. A New Method for Examining the Cost Savings of Reducing COPD Exacerbations

    Article • PharmacoEconomics, September 2010, Springer Science + Business Media

    Dr Douglas Mapel

  29. Predicting risk of airflow obstruction in primary care: Validation of the lung function questionnaire (LFQ)

    Article • Respiratory Medicine, August 2010, Elsevier

    Dr Douglas Mapel

  30. Comparative Effectiveness Of Budesonide / Formoterol Fumarate Dehydrate Combination And Fluticasone Propionate / Salmeterol Combination For The Management Of Chronic Obstructive Pulmonary Disease (COPD)

    Article • May 2010, American Thoracic Society

    Dr Douglas Mapel

  31. Outcomes Post-hospitalization Or Following An Emergency Department Visit Related To Chronic Obstructive Pulmonary Disease (COPD): Data From Administrative Claims

    Article • May 2010, American Thoracic Society

    Dr Douglas Mapel

  32. The role of combination inhaled corticosteroid/long-acting β-agonist therapy in COPD management

    Article • Primary Care Respiratory Journal, March 2010, Springer Science + Business Media

    Dr Douglas Mapel

  33. Pneumonia among COPD patients using inhaled corticosteroids and long-acting bronchodilators

    Article • Primary Care Respiratory Journal, January 2010, Springer Science + Business Media

    Dr Douglas Mapel

  34. ECONOMIC BURDEN OF CHRONIC BRONCHITIS IN MANAGED CARE POPULATION: A RETROSPECTIVE COHORT STUDY

    Article • CHEST Journal, October 2009, Elsevier

    Dr Douglas Mapel

  35. SEVERITY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE AT THE TIME OF INITIAL DIAGNOSIS

    Article • CHEST Journal, October 2009, Elsevier

    Dr Douglas Mapel

  36. Cost-effectiveness of fluticasone propionate/salmeterol (500/50μg) in the treatment of COPD

    Article • Respiratory Medicine, January 2009, Elsevier

    Dr Douglas Mapel

  37. DEVELOPMENT OF THE LUNG FUNCTION QUESTIONNAIRE: A SCREENING TOOL TO IDENTIFY AIRFLOW OBSTRUCTION

    Article • CHEST Journal, October 2008, Elsevier

    Dr Douglas Mapel

  38. Predictive validity of short-form health survey [36 items] scales for chronic obstructive pulmonary disease exacerbation

    Article • Heart & Lung, September 2008, Elsevier

    Dr Douglas Mapel

  39. The Direct Medical Costs of Undiagnosed Chronic Obstructive Pulmonary Disease

    Article • Value in Health, July 2008, Elsevier

    Dr Douglas Mapel

  40. COPD as a Lung Disease with Systemic Consequences – Clinical Impact, Mechanisms, and Potential for Early Intervention

    Article • COPD Journal of Chronic Obstructive Pulmonary Disease, January 2008, Taylor & Francis

    Dr Douglas Mapel

  41. Survival Among Copd Patients Using Fluticasone/Salmeterol in Combination Versus Other Inhaled Steroids and Bronchodilators Alone

    Article • COPD Journal of Chronic Obstructive Pulmonary Disease, January 2007, Taylor & Francis

    Dr Douglas Mapel

  42. SURVIVAL AMONG CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS USING FLUTICASONE AND SALMETEROL IN COMBINATION VS OTHER INHALED STEROIDS AND LONG-ACTING BRONCHODILATORS ALONE

    Article • CHEST Journal, October 2006, Elsevier

    Dr Douglas Mapel

  43. Survival of COPD patients using inhaled corticosteroids and long-acting beta agonists

    Article • Respiratory Medicine, April 2006, Elsevier

    Dr Douglas Mapel

  44. Estimating the Cost of COPD—A Matter of Perspective

    Article • COPD Journal of Chronic Obstructive Pulmonary Disease, January 2006, Taylor & Francis

    Dr Douglas Mapel

  45. Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting β2-agonists in a health maintenance organization

    Article • Respiratory Medicine, December 2005, Elsevier

    Dr Douglas Mapel

  46. Predicting the costs of managing patients with chronic obstructive pulmonary disease

    Article • Respiratory Medicine, October 2005, Elsevier

    Dr Douglas Mapel

  47. Trends and Cardiovascular Co-morbidities of COPD Patients in the Veterans Administration Medical System, 1991–1999

    Article • COPD Journal of Chronic Obstructive Pulmonary Disease, January 2005, Taylor & Francis

    Dr Douglas Mapel

  48. Treatment Implications on Morbidity and Mortality in COPD

    Article • CHEST Journal, August 2004, Elsevier

    Dr Douglas Mapel

  49. Undiagnosed airflow obstruction: prevalence and implications

    Article • Current Opinion in Pulmonary Medicine, March 2003, Wolters Kluwer Health

    Dr Douglas Mapel

  50. Risk Stratification: A Practical Guide For Clinicians

    Article • CHEST Journal, January 2002, Elsevier

    Dr Douglas Mapel

  51. The Health Impact of Undiagnosed Airflow Obstruction in a National Sample of United States Adults

    Article • American Journal of Respiratory and Critical Care Medicine, August 2001, American Thoracic Society

    Dr Douglas Mapel

  52. Health Care Utilization in Chronic Obstructive Pulmonary Disease

    Article • Archives of Internal Medicine, September 2000, American Medical Association (AMA)

    Dr Douglas Mapel

  53. Hemoptysis Season

    Article • CHEST Journal, August 2000, Elsevier

    Dr Douglas Mapel

  54. Utilization in COPD

    Article • CHEST Journal, May 2000, Elsevier

    Dr Douglas Mapel

  55. The Environmental Epidemiology of Idiopathic Interstitial Lung Disease Including Sarcoidosis

    Article • Seminars in Respiratory and Critical Care Medicine, November 1999, Thieme Publishing Group

    Dr Douglas Mapel

  56. Corticosteroids and the Treatment of Idiopathic Pulmonary Fibrosis

    Article • CHEST Journal, October 1996, Elsevier

    Dr Douglas Mapel

  57. Adenocarcinoma of the lung presenting as a diffuse interstitial process in a 25-year-old man

    Article • Lung Cancer, September 1996, Elsevier

    Dr Douglas Mapel